Abstract
Camptothecins demonstrate a broad spectrum of antitumor activity. Although they are known to trap DNA topoisomerase I on DNA, form cleavable complexes, and generate DNA breaks upon collision with DNA or RNA polymerases, the precise mechanisms predictive for antitumor activity remain to be identified. Recent studies using panels of colorectal and breast cancer cell lines indicate that events downstream of cleavable complexes are more relevant. In this study, we chose SN-38, an active metabolite of irinotecan, to characterize DNA double strand breaks and repair mechanisms induced by this type of drugs using a human head and neck squamous cell carcinoma cell line A253. The results showed that 2-h exposure of cells to an IC(50) concentration of SN-38 induces biphasic DNA double-strand break (DSBs): an immediate phase, which was greatly reduced within 8 h, and a lagging phase, culminating 24 h after drug removal. Three DNA double-strand break repair protein complexes were activated: DNA-dependent protein kinase (DNA-PK), NBS1-MRE11-RAD50, and BRCA1. Aphidicolin, a DNA polymerase inhibitor, abolished both phase I DSBs and the activation of repair protein complexes, suggesting that they resulted from the collision between the cleavabl...Continue Reading
References
Jun 1, 1992·International Journal of Radiation Biology·S J Falk, P J Smith
Oct 1, 1990·International Journal of Radiation Biology·M Frankenberg-Schwager, D Frankenberg
Jun 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·C B BennettM A Resnick
Jul 1, 1997·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·J A CollinsM C Willingham
Oct 23, 1997·Nucleic Acids Research·J Wu, L F Liu
Nov 5, 1997·Experimental Cell Research·J I NagyE L Hertzberg
Oct 23, 1997·American Journal of Human Genetics·E A Hendrickson
Mar 28, 1998·The Journal of Biological Chemistry·Z M YuanD Kufe
Aug 26, 1998·Cell·S E LeeJ E Haber
Mar 4, 1999·The EMBO Journal·R G ShaoY Pommier
Apr 23, 1999·The Journal of Biological Chemistry·G ChenE Y Lee
May 27, 1999·Genes & Development·T T Paull, M Gellert
Oct 3, 1999·Nature Genetics·W GoedeckeC Heyting
Nov 5, 1999·Science·D CortezS J Elledge
Feb 29, 2000·Molecular Pharmacology·M B YinY M Rustum
Mar 21, 2000·Nature·J S LeeJ H Chung
Apr 8, 2000·Current Opinion in Genetics & Development·P Karran
Jun 6, 2000·Nature·S ZhaoE Y Lee
Jun 6, 2000·Nature·X WuD T Weaver
Jul 25, 2000·The Journal of Biological Chemistry·S ShangaryR Baskaran
Feb 13, 2001·Nucleic Acids Research·C ArnaudeauT Helleday
Mar 10, 2001·Nature Genetics·K K Khanna, S P Jackson
Mar 21, 2001·Nature Reviews. Genetics·D C van GentR Kanaar
May 17, 2001·Proceedings of the National Academy of Sciences of the United States of America·T T PaullM Gellert
Aug 16, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Yves PommierGary S. Laco
Aug 16, 2001·The Journal of Biological Chemistry·N Chiba, J D Parvin
Citations
Jan 12, 2011·Investigational New Drugs·David DavidsonLawrence Panasci
Dec 4, 2003·Mutation Research·Yves PommierKurt W Kohn
Jun 27, 2003·DNA Repair·John C ConnellyDavid R F Leach
Jun 6, 2007·The Pharmacogenomics Journal·A RuzzoM Magnani
Aug 20, 2003·Molecular Biology of the Cell·Tone SandalStein O Døskeland
May 12, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B BurtnessA A Forastiere
Jan 12, 2005·Nucleic Acids Research·Sandrine JacobFrançoise Praz
Aug 2, 2005·Molecular and Cellular Biology·Nasrollah Saleh-GohariThomas Helleday
Jun 17, 2010·Chemotherapy·Sreenivasulu ChintalaYoucef M Rustum
Nov 13, 2009·Journal of Cancer Research and Clinical Oncology·Mehmet ArtacBurhan Savas
Sep 30, 2015·Journal of Cellular and Molecular Medicine·Kwanghyun LeeBong-Gun Ju
Dec 21, 2004·International Journal of Cancer. Journal International Du Cancer·Qi ChenAnlong Xu
Aug 2, 2002·Biochemical and Biophysical Research Communications·Ming-biao YinYoucef M Rustum
Aug 23, 2005·Cancer Chemotherapy and Biological Response Modifiers·Max KreditorHoward S Hochster
Jun 2, 2015·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Elena De MattiaGiuseppe Toffoli
Oct 19, 2006·Neuroscience·S F el-Khamisy, K W Caldecott
Nov 3, 2011·PloS One·Raymond MoralesIsaac K O Cann
Dec 14, 2012·PloS One·Giordano ManciniAlessandro Desideri
Aug 23, 2012·PloS One·Jay YangGrant W Brown
Apr 27, 2012·PloS One·Samta JainChris van der Does
Jun 4, 2016·Journal of Medicinal Chemistry·Sébastien L DegorceAndrew G Thomason
Dec 17, 2011·PloS One·Amit RoyHemanta K Majumder
Mar 25, 2017·The Journal of Eukaryotic Microbiology·Jürgen VoigtJohannes Wöstemeyer
Jul 28, 2006·Organic Letters·Mark A ElbanSidney M Hecht
Apr 17, 2003·British Journal of Cancer·G P FeeneyP J Smith
Jan 13, 2006·Oncogene·T FurutaY Pommier
Jul 19, 2005·Molecular Pharmacology·Hua-Rui LuJian Ding
Jul 22, 2004·Molecular Pharmacology·Tracy E KimYung-Chi Cheng
Jun 1, 2005·Immunological Investigations·Yihuai GaoShufeng Zhou
Apr 3, 2013·International Journal of Oncology·Amélie PetitprezAnnette K Larsen
Jun 16, 2006·Mutagenesis·Sherif F El-Khamisy, Keith W Caldecott
Sep 15, 2010·Cancer Research·Raina A TamakawaJudy M Y Wong
Mar 1, 2014·Molecular Cancer Therapeutics·Makiko TaharaKokichi Sugano
Aug 22, 2018·ACS Medicinal Chemistry Letters·Bernard BarlaamBaochang Zhai